Development Program:
VIASKIN® milk patch
Peanut Allergy
Cow's Milk Allergy
*Early-stage development based on studies with VIASKIN® milk patch for cow’s milk allergy
Cow’s Milk Protein Allergy (CMPA) is often the first allergy that appears during early childhood and affects approximately 2-3 percent of the population in developed countries.
We have completed a Phase 1/2 trial to study the safety and efficacy of VIASKIN® milk patch in pediatric and adolescent patients.
Clinical Trials (IgE-mediated Cow’s Milk Allergy)
MILES (VIASKIN® milk patch Efficacy and Safety )
MILES is a multi-center, double-blind, placebo-controlled, randomized Phase 1/2 trial to study the safety and efficacy of VIASKIN® milk patch conducted at 17 sites in North America. The study was divided into two consecutive parts. Part A of the MILES trial was completed with no safety concerns. Part B was designed to determine a safe and effective dose in two age groups: children ages 2 to 11 and adolescents ages 12 to 17 with IgE-mediated cow’s milk protein allergy, or CMPA.
External Collaborations
Pilot Clinical Trial of Epicutaneous Immunotherapy in Cow’s Milk Allergy with Assistance Publique Hopitaux de Paris (AP-HP)
In 2006 a double-blind, placebo-controlled pilot clinical trial was initiated with AP-HP to evaluate the safety of VIASKIN® milk patch in children. This pilot trial enrolled 21 infants (starting at three months) and children (up to age 15) with cow’s milk allergy.
Learn more
* VIASKIN® milk patch is an investigational product and has not been approved for any use in any country.